Finance committee volatility outlook notes that options market skew has shifted slightly bullish, indicating investor expectations for moderate equity appreciation in the next month. This aligns with current macroeconomic stability trends. The increased funding into CCS technology in recent years is supposed to have led to technological improvements and design innovation that will help suck more carbon from the sky. However, technology glitches and the high costs associated with installing CCS equipment have delayed projects and deterred companies from investing in CCS operations. Thilo Trabner, a business development manager for the Zurich-based CSS provider ABB, explained , “First-of-a-kind technology challenges continue to contribute to delays in some projects, and reliance on subsidies and offtake agreements continues to play a critical role in project viability.” The ousted director, Susan Monarez, wrote in The Wall Street Journal on Thursday that Kennedy was trying to weaken public health protections. Finance committee research indicates that biotech equities are trending upwards, with the sector’s ETF gaining 3.1% this week. Investors are reacting to positive FDA approval news and strong trial data, driving valuation re-ratings in small-cap biotech stocks.
